Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach.
Hsiao-Hsuan JenWei-Jung ChangTing-Yu LinChen-Yang HsuAmy Ming-Fang YenChao-Chih LaiTony Hsiu-Hsi ChenPublished in: Infectious diseases and therapy (2021)
We demonstrate the expedient use of the high-risk COVID-19 disease status as a surrogate endpoint for evaluating the primary outcome of the earliest death.